Pharma Funds Performance

After two years of strong gains, pharma fund returns slip in 2025 amid US tariff uncertainty and sector volatility, though structural tailwinds keep long-term view intact

Altogether, 26 funds focused on pharma and healthcare collectively manage Rs 30,306 crore. Some of them offer exposure to global pharma stocks

Improving US generic market outlook is driving the current rebound, but brace for periodic drawdowns

In the year to date, the Nifty pharma index has returned 8.8 per cent, with 10 of its constituents giving negative returns

Easing of supply chain issues, hydroxychloroquine opportunity boost sentiments

Money managers say domestic API manufacturers can stall impact from Chinese lockdown

Investors, however, need to understand their prospects before deciding to raise their exposure to these export-oriented sectors

IT and pharma funds have returned 4.4% and 1.77% in the past month, respectively

Attractive valuations have spurred fund houses to launch new funds in this category as well

The funds have shed 8.5%, even as Sensex has returned 16%; effectively that's a 25% underperformance